Genentech announced results from its Phase 3 study of Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) for the treatment of previously treated (recurrent), platinum-sensitive ovarian cancer. This trial was a multicenter, randomized, double-blind, placebo-controlled study in 484 women with platinum-sensitive recurrent ovarian, primary peritoneal or fallopian tube cancer. The primary efficacy endpoint is progression free survival or PFS. The study showed that women who received a combination of Avastin and chemotherapy, followed by the continued use of Avastin alone, lived longer without their disease worsening (PFS), compared to women who received chemotherapy alone.
Avastin (bevacizumab) is biologic antibody designed to specifically bind to a protein called VEGF that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels.
For more information call (888) 662-6728 or visit www.avastin.com.